aboutus
 

About Us

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company has two product candidates in clinical development:

  • The hCDR1 peptide is a novel compound, working via a novel mechanism of action, for the treatment of Systemic Lupus Erythematosus (“SLE”). hCDR1 has completed three clinical trials involving more than 400 patients.
  • Recombinant Erythropoietin (rHuEPO) is a known compound we are developing for the prolongation of multiple myeloma (MM) advanced-stage patients’ survival and improvement of their quality of life.